Jasper Therapeutics, Inc. (JSPR)
JSPRNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$14.75
-1.37 (-8.50%) today
At the close, Nov 10, 4:00 PM ET. After hours $14.75 –
- Market cap
- $16.36m
- P/E
- –
- EPS, last 4 quarters
- $-62.16
- Dividend yield
- –
- Day range
- $14.09 to $15.87
- 52-week range
- $9.45 to $72.60
- Average volume
- 14.5k
- Previous close
- $16.12
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $330.00, +2137.3% from here
Earnings
next estimate $-1.80Next report
Sep 2025
-11.9%
Dec 2025
+59.5%
Mar 2026
+17.4%
Jun 2026
+35.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$19.17m | -$15.84m | -$10.95m | -$9.21m |
| Net income | -$18.74m | -$9.10m | -$1.17m | -$2.76m |
News
8 latest- Jasper Therapeutics Consensus Price Target Increased by 2,900% to $267.75Fintel · 1 day ago
- Jasper Therapeutics, Inc. Announces Results of Warrant Purchase OfferFintel · 1 day ago
- Jasper Therapeutics, Inc. Announces 1-for-30 Reverse Stock SplitFintel · 6 days ago
- Jasper Therapeutics To Implement 1-for-30 Reverse Stock Split RTTNews · 6 days ago
- Zoetis Gears Up to Report Q3 Earnings: Here's What to ExpectZacks · Nov 3, 2026
- Jasper Therapeutics Nears IgAN Data Readout, Plans FSGS Study In 2027 RTTNews · Oct 15, 2026
- Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92Fintel · Oct 2, 2026
- Jasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock Up RTTNews · Sep 16, 2026
The company
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Jasper is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- jaspertherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.